Protein tyrosine kinase inhibitors in cancer therapy

被引：5

作者：

Boutayeb, S. ^{[1
]}

Zakkouri, F. Z. ^{[1
]}

Aitelhaj, M. ^{[1
]}

Mesmoudi, M. ^{[1
]}

Boutayeb, A. ^{[2
]}

Boutayeb, W. ^{[2
]}

Mrabti, H. ^{[1
]}

Errihani, H. ^{[1
]}

机构：

[1] CHU Ibn Slum, Inst Natl Oncol, Serv Oncol Med, Rabat, Morocco

[2] Univ Mohammed 1, Fac Sci, Unite Biostat, Oujda, Morocco

来源：

PATHOLOGIE BIOLOGIE | 2012年 / 60卷 / 04期

关键词：

Tyrosine kinase inhibitor; Cancer; Signal transduction; CELL LUNG-CANCER; PHASE-III; IMATINIB MESYLATE; DOUBLE-BLIND; VANDETANIB; SUNITINIB; ERLOTINIB; 1ST-LINE;

D O I：

10.1016/j.patbio.2012.05.007

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

The tyrosine kinase inhibitors (TKI) are small molecules of low molecular weight that inhibit tyrosine kinases, enzymes responsible for the activation of signal transduction cascades. Currently, a number of TKI received approval in various cancers, while others are in clinical development process: TKI are specifically clinically active when they target a tyrosine kinase (TK) with constitutional activity subsequent to a mutation, being then a master-gene driving transformation and tumour progression. Already, this drug-family provides a major therapeutic weapon against cancer. (C) 2012 Elsevier Masson SAS. All rights reserved.

引用

页码：229 / 233

页数：5

共 50 条

[31] Tyrphostins, inhibitors of protein tyrosine kinase, in restenosis
Golomb, G
Fishbein, I
ADVANCED DRUG DELIVERY REVIEWS, 1997, 24 (01) : 53 - 62
[32] Protein tyrosine kinase inhibitors as therapeutic agents
Levitzki, A
BIOORGANIC CHEMISTRY OF BIOLOGICAL SIGNAL TRANSDUCTION, 2001, 211 : 1 - 15
[33] Protein tyrosine kinase inhibitors as anticancer agents
Supuran, CT
Scozzafava, A
EXPERT OPINION ON THERAPEUTIC PATENTS, 2004, 14 (01) : 35 - 53
[34] New targets for therapy in breast cancer: Small molecule tyrosine kinase inhibitors
Nancy U Lin
Eric P Winer
Breast Cancer Research, 6
[35] Tyrosine kinase inhibitors as induction therapy in nonsmall-cell lung cancer
Gong, Juejun
Zhang, Li
CURRENT OPINION IN ONCOLOGY, 2021, 33 (01) : 55 - 58
[36] Receptor tyrosine kinase inhibitors: molecularly targeted drugs for veterinary cancer therapy
Bavcar, S.
Argyle, D. J.
VETERINARY AND COMPARATIVE ONCOLOGY, 2012, 10 (03) : 163 - 173
[37] New targets for therapy in breast cancer - Small molecule tyrosine kinase inhibitors
Lin, NU
Winer, EP
BREAST CANCER RESEARCH, 2004, 6 (05) : 204 - 210
[38] Histone deacetylase inhibitors merged with protein tyrosine kinase inhibitors
Zhou, Nan
Xu, Wenfang
Zhang, Yingjie
DRUG DISCOVERIES AND THERAPEUTICS, 2015, 9 (03): : 147 - 155
[39] Role of Tyrosine Kinase Inhibitors in Lung Cancer
Ansari, J.
Palmer, D. H.
Rea, D. W.
Hussain, S. A.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2009, 9 (05) : 569 - 575
[40] Novel Tyrosine Kinase Inhibitors in Lung Cancer
Zhou, Caicun
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S86 - S87

← 1 2 3 4 5 →